Disease · MONDO_0001475

neutropenia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. neutropenia. Diseases, record MONDO_0001475. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001475

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: neutropenia; Open Targets
Open Targets ID: MONDO_0001475; Open Targets
Other names: Decreased total neutrophil count, Low blood neutrophil count, Low neutrophil count, Neutropoenia, Peripheral neutropenia, neutropenic disorder; Open Targets
Disease Ontology: DOID:1227; Disease Ontology
MeSH: D009503; MeSH
Highest stage of its drugs: Approval, for 4 of its 69 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs69

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEGFILGRASTIM	CHEMBL1201568	Protein	Approval	DailyMed and EMA Human Drugs	22	14	10	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	19	10	8	Drugs and targets
EFLAPEGRASTIM	CHEMBL3833384	Protein	Approval	TTD	5	4	4	Drugs and targets
POSACONAZOLE	CHEMBL1397	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
CASPOFUNGIN ACETATE	CHEMBL5314378	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
VANCOMYCIN	CHEMBL262777	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
AMPHOTERICIN B	CHEMBL267345	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DAPTOMYCIN	CHEMBL387675	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
LENOGRASTIM	CHEMBL2109128	Protein	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
CEFEPIME	CHEMBL186	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 69

See all 69 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CSF3R	Granulocyte colony-stimulating factor receptor	4	Granulocyte colony stimulating factor receptor agonist	Approval	https://conductscience.org/library/genes/1441	Drugs and targets
TOP1	DNA topoisomerase 1	3	DNA topoisomerase I inhibitor	Phase 2	https://conductscience.org/library/genes/7150	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	2	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CSF2RA	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1438	Drugs and targets
CSF2RB	Granulocyte-macrophage colony-stimulating factor receptor	1	Granulocyte-macrophage colony-stimulating factor receptor agonist	Phase 1	https://conductscience.org/library/genes/1439	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
CXCR4	C-X-C chemokine receptor type 4	1	C-X-C chemokine receptor type 4 partial agonist	Phase 1/2	https://conductscience.org/library/genes/7852	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials76

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02643420	SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)	Phase 3	406	2022-03-02	Neutropenia, Breast Cancer	EFLAPEGRASTIM, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT02953340	SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide	Phase 3	237	2022-03-02	Neutropenia, Breast Cancer	EFLAPEGRASTIM, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT01021683	The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants		203	2013-07-03	Hematologic Neoplasms, Neutropenia, Fever	ITRACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01724866	Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer	Phase 2	148	2022-04-15	Neutropenia	EFLAPEGRASTIM, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT00150345	Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients	Phase 3	147	2010-08-18	Possible Fungal Infection	VORICONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT01716234	A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)	Phase 1	142	2016-04-15	Fungal Infections	POSACONAZOLE	Its record names the disease	ClinicalTrials.gov
NCT00627393	Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)	Phase 3	114	2014-12-23	Neutropenia, Infection	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT03485950	Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam	Phase 2	100	2021-07-20	Other Infectious Diseases	CEFTOLOZANE, TAZOBACTAM	Its record names the disease	ClinicalTrials.gov
NCT03384940	DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)	Phase 2	86	2021-08-24	Colorectal Neoplasm	TRASTUZUMAB DERUXTECAN	Its record names the disease	ClinicalTrials.gov
NCT00003910	Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia	Phase 2	59	2013-05-27	Leukemia	CYCLOPHOSPHAMIDE, METHOTREXATE, PREDNISONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 76

See all 76 trials

Comparisons in its trials40

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC: Number of Participants With Neutropenic Complications in Cycle 1	8 of 196	8 of 210	406	NCT02643420	Trial comparisons
Arm 1: SPI-2012 and TC vs Arm 2: Pegfilgrastim and TC: Number of Participants With Febrile Neutropenia (FN) in Cycle 1	4 of 196	2 of 210	406	NCT02643420	Trial comparisons
(Arm 1): SPI-2012 and TC vs (Arm 2): Pegfilgrastim and TC: Number of Participants With Febrile Neutropenia (FN) in Cycle 1	1 of 118	4 of 119	237	NCT02953340	Trial comparisons
(Arm 1): SPI-2012 and TC vs (Arm 2): Pegfilgrastim and TC: Number of Participants With Neutropenic Complications in Cycle 1	1 of 118	5 of 119	237	NCT02953340	Trial comparisons
Immediate Voriconazole vs Deferred Voriconazole Treatment: serious adverse events	8 of 81	8 of 66	147	NCT00150345	Trial comparisons
Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants Assessed as Needing Further Antineoplastic Therapy as Planned	42 of 68	32 of 54	122	NCT00150345	Trial comparisons
Immediate Voriconazole vs Deferred Voriconazole Treatment: Number of Participants With Defervescence Day 5 (4 Days After Initiation of Study Treatment)	32 of 68	28 of 54	122	NCT00150345	Trial comparisons
Granulocyte Arm vs Control Arm: Long-term Survival	20 of 56	30 of 58	114	NCT00627393	Trial comparisons
Granulocyte Arm vs Control Arm: serious adverse events	26 of 56	25 of 58	114	NCT00627393	Trial comparisons
Ceftolozane/Tazobactam Arm vs Standard of Care (SOC) Arm: Number of Participants With Infection-related Mortality in the MITT Analysis Set at LFU	0 of 47	0 of 50	97	NCT03485950	Trial comparisons

1 to 10 of 40

See all 40 comparisons in its trials

Papers from its trials34

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26619462	RESULT	1	PubMed
25020130	RESULT	1	PubMed
24618935	RESULT	1	PubMed
22271702	RESULT	1	PubMed
21837771	RESULT	1	PubMed
21835955	RESULT	1	PubMed
21394050	RESULT	1	PubMed
20431381	RESULT	1	PubMed
20231680	RESULT	1	PubMed
15806544	RESULT	1	PubMed

1 to 10 of 34

See all 34 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001475

GET https://conductscience.org/api/diseases/v1/MONDO_0001475/drugs?page=2

API reference For AI assistants